Skip to main content
. 2019 Oct;7(20):550. doi: 10.21037/atm.2019.09.101

Table 3. The association between TIM-3 −1516G/T SNP and the risk of cancer.

Genetic model Group No. of studies Heterogeneity test Model selected OR (95% CI)
I2 (%) P
T vs. G Total 7 39.50 0.128 R 1.33 (1.14–1.54)
Digestive system cancer 3 48.10 0.123 R 1.62 (1.18–2.22)
Non-digestive system cancer 4 0.00 0.901 R 1.15 (0.94–1.41)
Hospital-control 5 54.90 0.064 R 1.38 (1.03–1.83)
TT vs. (GG+GT) Total 7 0.00 0.998 R 6.09 (1.27–29.00)
Hospital-control 5 0.00 0.994 R 5.87 (0.68–50.44)
(TT+GT) vs. GG Total 7 28.70 0.209 R 1.33 (1.14–1.56)
Digestive system cancer 3 39.70 0.173 R 1.61 (1.18–2.18)
Non-digestive system cancer 4 28.70 0.209 R 1.17 (0.95–1.44)
Hospital-control 5 47.60 0.106 R 1.31 (1.08–1.58)
TT vs. GG Total 7 0.00 0.999 R 6.61 (1.39–31.48)
Hospital-control 5 0.00 0.988 R 6.40 (0.74–55.10)
GT vs. GG Total 7 10.60 0.348 R 1.31 (1.12–1.53)
Digestive system cancer 3 26.30 0.254 R 1.53 (1.16–2.02)
Non-digestive system cancer 4 0.00 0.894 R 1.32 (1.11–1.55)
Hospital-control 5 35.60 0.184 R 1.33 (1.04–1.70)

Some I2 and P values were not available because of only one study in the subgroup. Some figures were not available in the subgroup analysis based on cancer type or the source of control group in some models due to fewer than one study in the subgroup. R, random-effects model; SNP, single nucleotide polymorphism; OR, odds ratio; CI, confidence interval.